User:Mr. Ibrahem/Mirvetuximab soravtansine

Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used to treat certain types of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Specifically it is for cases that are folate receptor alpha (FRα) positive that have failed other treatments. It is given by gradual injection into a vein.

Common side effects include vision problems, tiredness, liver problems, nausea, abdominal pain, low white blood cells, peripheral neuropathy, diarrhea, constipation, low magnesium, and low hemoglobin. Other side effects may include pneumonitis. Use in pregnancy may harm the baby. It is a monoclonal antibody directed at FRα attached to a microtubule inhibitor.

Mirvetuximab soravtansine was approved for medical use in the United States in 2022. It is available as an orphan medication in Europe. In the United States it costs about 25,000 USD every three weeks as of 2022.